Acalabrutinib Impurity 13
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

1420478-90-5Acalabrutinib Impurity 13

● In Stock

Catalogue No.:VE0023233
CAS No.:1420478-90-5
Mol. Formula:C22H21N7O
Mol. Weight:399.45 g/mol

Additional information on CAS 1420478-90-5

Parent drug

Acalabrutinib

IUPAC Name

(S)-4-(8-amino-3-(pyrrolidin-2-yl)imidazo[1, 5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide

Pharmacopoeial Synonyms

N/A

Other Synonyms

N/A

Smiles

O=C(C1=CC=C(C2=C(C(N)=NC=C3)N3C([C@H]4NCCC4)=N2)C=C1)NC5=CC=CC=N5

InChI

InChI=1S/C22H21N7O/c23-20-19-18(28-21(16-4-3-11-24-16)29(19)13-12-26-20)14-6-8-15(9-7-14)22(30)27-17-5-1-2-10-25-17/h1-2, 5-10, 12-13, 16, 24H, 3-4, 11H2, (H2, 23, 26)(H, 25, 27, 30)/t16-/m0/s1

Description

The Acalabrutinib Impurity 13 standard is a well-characterized compound that aligns with key regulatory guidelines | including USP | EMA | JP | and BP. It plays a crucial role in analytical method development | method validation (AMV) | and quality control (QC) processes | particularly in the manufacturing of Acalabrutinib. This impurity standard is valuable for both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA) | ensuring reliable and precise analytical outcomes. To further support research and development | it comes with a comprehensive Structure Elucidation Report (SER) | providing detailed insights for advanced analysis.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url